Hikma Pharmaceuticals has announced the appointment of Cynthia Schwalm as an independent non-executive director, effective from 1 June 2019.
Cynthia was president and CEO of the North American divisions of the global pharmaceutical companies Ipsen and Eisai, and also held leadership positions at Amgen and Johnson & Johnson. She is currently a non-executive director of Caladrius Biosciences, Kadman Group and G1 Therapeutics, where she chairs the Compensation Committee. She also holds a BSN from the University of Delaware and EMBA from Wharton at the University of Pennsylvania.
“I am very pleased that Cynthia will be joining the Hikma Board. She brings extensive, proven experience in providing strong leadership through transformation,” said Said Darwazah, executive chairman. “Her extensive commercial and leadership experience in the pharmaceutical and biotech industries, as well as her experience as a healthcare practitioner will bring a fresh perspective to the board and our next stage of growth.”